img
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 737817

European Heart Rhythm Association (EHRA) Congress 23 – 25 April 2021

The 2021 congress of the European Heart Rhythm Association (EHRA) took place online, with more than 3,300 delegates registered. EHRA brings together scientists, healthcare professionals and other players involved in cardiac arrhythmia management from across the globe. MicroPort CRM sponsored a 30-minute symposium on promising advances in heart failure patient management, during which Prof. Frédéric Anselme (University Hospital […]

The first enrollment in the ASTRAL-4LV clinical trial – 3 December 2020 

The first implantation of Axone as part of the ASTRAL-4LV study was successfully performed on December 3, 2020, by Professor Frédéric Anselme at the Rouen University Hospital in France. The purpose of the ASTRAL-4LV study is to assess the chronic safety and performance of the Axone lead for cardiac resynchronization therapy (CRT). “Approximately 30% of […]

European Heart Rhythm Association (EHRA) Congress 17-19 March 2019

INNOVATION LAB An innovation lab was present at MicroPort CRM’s booth, dedicated to the presentation of the Axone project and a demonstration of the product. In addition, an implant simulator was made available to physicians, to provide them with a hands-on handling experience on the Axone system. During the congress, a total of 135 physicians visited the […]